See more : Fluor Corporation (FLRAP) Income Statement Analysis – Financial Results
Complete financial analysis of HUTCHMED (China) Limited (HCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HUTCHMED (China) Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- CNS Co.,Ltd (4076.T) Income Statement Analysis – Financial Results
- Boxlight Corporation (BOXL) Income Statement Analysis – Financial Results
- Beyon3D Ltd. (BYON.TA) Income Statement Analysis – Financial Results
- Danske Invest – Danmark Indeks ex OMXC20 (DKIDKIEXOMXC20D.CO) Income Statement Analysis – Financial Results
- Carmat SA (ALCAR.PA) Income Statement Analysis – Financial Results
HUTCHMED (China) Limited (HCM)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hutch-med.com
About HUTCHMED (China) Limited
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 838.00M | 426.41M | 356.13M | 227.98M | 204.89M | 214.11M | 241.20M | 216.08M | 178.20M | 91.81M | 45.97M | 195.39M | 166.92M | 134.51M | 111.00M | 86.97M | 65.11M | 50.43M | 37.86M |
| Cost of Revenue | 384.45M | 311.10M | 258.23M | 188.52M | 160.15M | 143.94M | 175.82M | 156.33M | 110.78M | 72.05M | 22.21M | 99.40M | 74.16M | 54.64M | 44.59M | 36.13M | 27.66M | 21.32M | 14.62M |
| Gross Profit | 453.55M | 115.31M | 97.89M | 39.46M | 44.74M | 70.17M | 65.38M | 59.75M | 67.43M | 19.76M | 23.76M | 95.99M | 92.77M | 79.87M | 66.41M | 50.84M | 37.45M | 29.11M | 23.24M |
| Gross Profit Ratio | 54.12% | 27.04% | 27.49% | 17.31% | 21.84% | 32.77% | 27.11% | 27.65% | 37.84% | 21.53% | 51.69% | 49.13% | 55.57% | 59.38% | 59.83% | 58.46% | 57.52% | 57.72% | 61.40% |
| Research & Development | 303.06M | 267.59M | 207.45M | 111.23M | 91.94M | 78.82M | 50.68M | 66.87M | 47.37M | 33.47M | 23.44M | 5.89M | 7.29M | 6.41M | 3.86M | 8.81M | 5.64M | 2.77M | 2.05M |
| General & Administrative | 79.78M | 92.17M | 89.30M | 50.02M | 39.21M | 30.91M | 23.96M | 21.58M | 19.62M | 22.57M | 21.30M | 35.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 53.39M | 43.93M | 37.83M | 11.33M | 13.72M | 17.74M | 19.32M | 18.00M | 10.21M | 4.11M | 3.45M | 62.68M | 56.50M | 52.70M | 44.81M | 31.74M | 23.09M | 16.04M | 18.20M |
| SG&A | 133.18M | 136.11M | 127.13M | 61.35M | 52.93M | 48.65M | 43.28M | 39.58M | 29.83M | 26.68M | 24.75M | 98.41M | 56.50M | 52.70M | 44.81M | 31.74M | 23.09M | 16.04M | 18.20M |
| Other Expenses | 0.00 | 119.31M | 91.64M | 63.54M | 44.88M | -781.00K | 116.00K | 609.00K | 184.00K | 261.00K | 65.00K | -1.01M | 23.39M | -225.46K | -282.96K | -1.22M | -937.60K | -557.58K | -175.47K |
| Operating Expenses | 436.23M | 523.00M | 426.21M | 236.13M | 189.76M | 161.01M | 118.80M | 106.59M | 77.20M | 26.87M | 23.14M | 95.36M | 87.18M | 82.46M | 71.51M | 64.98M | 47.36M | 34.50M | 29.16M |
| Cost & Expenses | 819.62M | 834.10M | 684.45M | 424.64M | 349.91M | 304.95M | 294.62M | 262.92M | 187.97M | 98.92M | 45.35M | 194.76M | 161.34M | 137.10M | 116.10M | 101.11M | 75.01M | 55.82M | 43.77M |
| Interest Income | 36.15M | 9.60M | 2.08M | 3.24M | 4.94M | 5.98M | 1.22M | 502.00K | 451.00K | 559.00K | 451.00K | 578.00K | 133.65K | 225.46K | 282.96K | 1.22M | 937.60K | 559.54K | 175.47K |
| Interest Expense | 759.00K | 652.00K | 592.00K | 787.00K | 1.03M | 1.01M | 1.46M | 1.63M | 1.40M | 1.05M | 1.01M | 737.00K | 561.03K | 402.38K | 399.37K | 527.87K | 299.15K | 388.73K | 495.45K |
| Depreciation & Amortization | 8.21M | 8.66M | 7.19M | 6.06M | 4.94M | 3.59M | 2.58M | 2.30M | 2.02M | 1.27M | 963.00K | 4.05M | 4.56M | 4.58M | 4.57M | 4.65M | 3.80M | 2.87M | 2.32M |
| EBITDA | 25.53M | -401.11M | -207.96M | -182.89M | -135.13M | -82.06M | -49.50M | -43.39M | -7.16M | -17.17M | 1.58M | -6.79M | 10.20M | 2.37M | -46.89K | -9.58M | -5.92M | -2.51M | -3.42M |
| EBITDA Ratio | 3.05% | -94.07% | -92.46% | -80.22% | -65.95% | -38.32% | -20.52% | -20.08% | -4.00% | -6.36% | 3.44% | -3.48% | 6.11% | 2.01% | 0.13% | -10.88% | -8.61% | -4.83% | -9.51% |
| Operating Income | 18.38M | -409.77M | -336.46M | -188.95M | -145.02M | -92.64M | -53.42M | -46.70M | -9.77M | 8.10M | 11.56M | 12.11M | 5.39M | -2.21M | -4.61M | -14.23M | -9.72M | -5.38M | -5.73M |
| Operating Income Ratio | 2.19% | -96.10% | -94.48% | -82.88% | -70.78% | -43.27% | -22.15% | -21.61% | -5.48% | 8.82% | 25.14% | 6.20% | 3.23% | -1.64% | -4.16% | -16.36% | -14.93% | -10.67% | -15.13% |
| Total Other Income/Expenses | 39.93M | -2.73M | 112.58M | 6.93M | 5.28M | 5.99M | -119.00K | -659.00K | -767.49K | 13.48M | 28.99M | -17.37M | -1.96M | -402.38K | -399.37K | -527.87K | -299.15K | -386.77K | -502.33K |
| Income Before Tax | 58.31M | -410.42M | -215.74M | -189.73M | -141.11M | -86.66M | -53.54M | -47.36M | -10.54M | 6.58M | 10.07M | 10.90M | 4.83M | -2.61M | -5.01M | -14.76M | -10.02M | -5.77M | -6.23M |
| Income Before Tax Ratio | 6.96% | -96.25% | -60.58% | -83.23% | -68.87% | -40.47% | -22.20% | -21.92% | -5.91% | 7.17% | 21.91% | 5.58% | 2.89% | -1.94% | -4.52% | -16.97% | -15.39% | -11.44% | -16.46% |
| Income Tax Expense | 4.51M | -283.00K | 11.92M | 4.83M | 3.27M | 3.96M | 3.08M | 4.33M | 1.61M | 1.34M | 1.05M | 4.16M | 3.14M | 2.58M | 2.07M | 1.50M | 837.21K | 1.96K | 141.06K |
| Net Income | 100.78M | -410.14M | -227.66M | -194.56M | -144.38M | -74.81M | -26.74M | 11.70M | 7.99M | 5.37M | 5.92M | 3.64M | 710.22K | -6.86M | -8.75M | -17.76M | -17.19M | -9.61M | -6.78M |
| Net Income Ratio | 12.03% | -96.18% | -63.93% | -85.34% | -70.47% | -34.94% | -11.08% | 5.41% | 4.49% | 5.85% | 12.87% | 1.86% | 0.43% | -5.10% | -7.88% | -20.41% | -26.40% | -19.05% | -17.90% |
| EPS | 0.59 | -0.48 | -0.29 | -0.28 | -0.22 | -0.11 | -0.04 | 0.10 | -0.32 | 0.05 | 0.06 | 0.04 | 0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| EPS Diluted | 0.58 | -0.48 | -0.29 | -0.28 | -0.22 | -0.11 | -0.04 | 0.10 | -0.32 | 0.05 | 0.06 | 0.03 | 0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| Weighted Avg Shares Out | 169.93M | 847.14M | 792.68M | 697.93M | 665.68M | 664.26M | 617.17M | 597.15M | 546.59M | 525.63M | 520.51M | 519.19M | 517.43M | 515.28M | 512.32M | 512.29M | 512.16M | 457.13M | 366.67M |
| Weighted Avg Shares Out (Dil) | 173.84M | 847.14M | 792.68M | 697.93M | 665.68M | 664.26M | 617.17M | 599.71M | 546.59M | 528.94M | 528.78M | 526.50M | 526.54M | 515.28M | 512.32M | 512.29M | 512.16M | 457.13M | 366.67M |
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
HUTCHMED (China) Limited (HCM) Q4 2023 Earnings Call Transcript
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
Source: https://incomestatements.info
Category: Stock Reports